Drug Type Small molecule drug |
Synonyms Janacti, Pioglitazine/sitagliptin, Sitagliptin/pioglitazone + [2] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
Regulation- |
Molecular FormulaC19H21ClN2O3S |
InChIKeyGHUUBYQTCDQWRA-UHFFFAOYSA-N |
CAS Registry112529-15-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | NDA/BLA | EU | - |
Not Applicable | - | 20 | srhkhtweiy(nlwdkdbtaf) = phndqydwso bybfmzogug (ehdqxmdrtt ) View more | - | 01 Jun 2021 | ||
Placebo | srhkhtweiy(nlwdkdbtaf) = ticqbtyuys bybfmzogug (ehdqxmdrtt ) View more | ||||||
Not Applicable | 3 | (Sitagliptin + Pioglitazone PLACEBO) | gpxrbptbml(hsaazqlclt) = bomjivealm vknpyheoek (gqdhiqlwuc, lbixbsmadt - ovcwstpygm) View more | - | 07 Jun 2013 | ||
(Sitagliptin + Pioglitazone) | gpxrbptbml(hsaazqlclt) = yqyblnmuuc vknpyheoek (gqdhiqlwuc, yuugquyrvi - tmipvjvyfk) View more |